Related Experiment Videos
Primary chemotherapy: a better overall therapeutic option for patients with breast cancer
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2024
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Thymic radiation is associated with worse outcomes in patients with NSCLC.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026